Acasti Pharma, Inc. (ACST) Q2 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for holding, ladies and gentlemen, and please remain on the line. The Acosti Pharma Conference will begin shortly. Thank you for your patience. Thank you. Good day, ladies and gentlemen, and welcome to the Acosti Pharma second quarter 2022 earnings call. At this time, all participants have been placed on the listen-only mode, and the floor will be open for questions and comments after the presentation. It is now my pleasure to turn the floor over to your host, David Waldman of Investor Relations. Sir, the floor is yours. Thank you, and good afternoon, everyone. I'd like to welcome you to Acosti Pharma's Fiscal 2022 Second Quarter Conference Call. On the call with us this afternoon are Jan D'Alvis, President and CEO, Dr. Pierre Lemieux, Chief Operating Officer, Canada, Chief Scientific Officer and Co-Founder, Dr. George Cotillo, Chief Operating Officer, U.S., Brian Ford, Chief Financial Officer, and Prashant Kohli, VP of Commercial Operations. We are planning for a Q&A session at the end of our prepared remarks, but if you have any remaining questions after the call or would like any additional information about the company, please contact Crescendo Communications at 212-671-1020. I'd also like to remind everyone that statements on this conference call that are not statements of historical or current fact constitute forward-looking information and within the meaning of the Canadian securities laws, and forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, the Securities Act of 1933, and the Securities Exchange Act of 1934. Such forward-looking statements involve known and unknown risks and uncertainties and other unknown factors that could cause the actual results of a cost CD to be materially different f...